Antiphospholipid Antibodies and the Antiphospholipid Syndrome: Clinical Significance and Treatment

 

 Buy Article Permissions and Reprints

ABSTRACT

This article provides a review of the various types of antiphospholipid (aPL) antibodies and antiphospholipid syndromes, their prevalence, presumed origin, relationship to autoimmunity in general, and their role in the body's defenses and apoptosis. New hypotheses such as the role of antibodies to β2 glycoprotein I (β2GPI) and the signaling of toll-like receptors are also discussed, as is the spectrum of clinical manifestations associated with the demonstration of these antibodies, now assumed to be “pathogenic.” A distinction is made between antibodies present in sera of patients with a variety of microangiopathic syndromes (MAPS; e.g., HELLP syndrome, thrombotic thrombocytopenic purpura, and thrombotic microangiopathic syndromes). In these conditions, the antibodies might not be “pathogenic” but, alternatively, generated by small vessel endothelial damage. These conditions are differentially referred to as microangiopathic antiphospholipid–associated syndromes, and they should be differentiated from the microvascular occlusions that are seen in the antiphospholipid syndrome. Current treatments of the antiphospholipid syndrome are briefly reviewed.

REFERENCES

• 1 Field S L, Brighton T A, McNeil H P, Chesterman C N. Recent insights into antiphospholipid antibody-mediated thrombosis.  Best Pract Res Clin Haematol. 1999;  12 407-422
  CrossrefPubMedGoogle Scholar
• 2 Meroni P L, Raschi E, Testoni C, Borghi M O. Endothelial cell activation by antiphospholipid antibodies.  Clin Immunol. 2004;  112 169-174
  CrossrefPubMedGoogle Scholar
• 3 Lockshin M D. Update on antiphospholipid syndrome.  Bull NYU Hosp Jt Dis. 2006;  64 57-59
  PubMedGoogle Scholar
• 4 Espinosa G, Cervera R, Font J, Shoenfeld Y. Antiphospholipid syndrome: pathogenic mechanisms.  Autoimmun Rev. 2003;  2 86-93
  CrossrefPubMedGoogle Scholar
• 5 Brandt J T, Triplett D A, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update.  Thromb Haemost. 1995;  74 1185-1190
  Article in Thieme ConnectPubMedGoogle Scholar
• 6 Fischetti F, Durigutto P, Pellis V et al.. Thrombus formation induced by antibodies to beta-2-glycoprotein I is complement dependent and requires a priming factor.  Blood. 2005;  106 2340-2346
  CrossrefPubMedGoogle Scholar
• 7 Czompoly T, Olasz K, Simon D et al.. A possible new bridge between innate and adaptive immunity: are the anti-mitochondrial citrate synthase autoantibodies components of the natural antibody network?.  Mol Immunol. 2006;  43 1761-1768
  CrossrefPubMedGoogle Scholar
• 8 Baumgarth N, Tung J W, Herzenberg L A. Inherent specificities in natural antibodies: a key to immune defense against pathogen invasion.  Springer Semin Immunopathol. 2005;  26 347-362
  CrossrefPubMedGoogle Scholar
• 9 Chang M K, Boullier A, Hartvigsen K et al.. The role of natural antibodies in atherogenesis.  J Lipid Res. 2005;  46 1353-1363
  CrossrefPubMedGoogle Scholar
• 10 Binder C J, Silverman G J. Natural antibodies and the autoimmunity of atherosclerosis.  Springer Semin Immunopathol. 2005;  26 385-404
  CrossrefPubMedGoogle Scholar
• 11 McIntyre J A, Wagenknecht D R, Faulk W P. Redox-reactive autoantibodies: detection and physiological relevance.  Autoimmun Rev. 2006;  5 76-83
  CrossrefPubMedGoogle Scholar
• 12 Blank M, Asherson R A, Cervera R, Shoenfeld Y. Antiphospholipid syndrome infectious origin.  J Clin Immunol. 2004;  24 12-23
  CrossrefPubMedGoogle Scholar
• 13 Shovman O, Gilburd B, Barzilai O et al.. Evaluation of the BioPlex 2200 ANA screen: analysis of 510 healthy subjects: incidence of natural/predictive autoantibodies.  Ann N Y Acad Sci. 2005;  1050 380-388
  CrossrefPubMedGoogle Scholar
• 14 Wananukul S, Voramethkul W, Kaewopas Y, Hanvivatvong O. Prevalence of positive antinuclear antibodies in healthy children.  Asian Pac J Allergy Immunol. 2005;  23 153-157
  PubMedGoogle Scholar
• 15 Shi W, Krilis S A, Chong B H, Gordon S, Chesterman C N. Prevalence of lupus anticoagulant and anticardiolipin antibodies in a healthy population.  Aust N Z J Med. 1990;  20 231-236
  PubMedGoogle Scholar
• 16 McIntyre J A, Wagenknecht D R, Faulk W P. Autoantibodies unmasked by redox reactions.  J Autoimmun. 2005;  24 311-317
  CrossrefPubMedGoogle Scholar
• 17 Reipert B M, Tanneberger S, Pannetta A et al.. Increase in autoantibodies against Fas (CD95) during carcinogenesis in the human colon: a hope for the immunoprevention of cancer?.  Cancer Immunol Immunother. 2005;  54 1038-1042
  PubMedGoogle Scholar
• 18 Rauch J, Subang R, D'Agnillo P, Koh J S, Levine J S. Apoptosis and the antiphospholipid syndrome.  J Autoimmun. 2000;  15 231-235
  CrossrefPubMedGoogle Scholar
• 19 Rauch J, D'Agnillo P, Subang R, Levine J S. Anti-phospholipid antibodies (aPL) and apoptosis: prothrombin-dependent aPL as a paradigm for phospholipid-dependent interactions with apoptotic cells.  Thromb Res. 2004;  114 371-382
  CrossrefPubMedGoogle Scholar
• 20 Miyakis S, Lockshin M H, Atsumi T et al.. International consensus statement on an update of the international classification for deinite antiphospholipid syndrome (APS).  J Thromb Haemost. 2006;  4 295-306
  CrossrefPubMedGoogle Scholar
• 21 Asherson R A. The catastrophic antiphospholipid syndrome syndrome.  J Rheumatol. 1992;  19 508-512
  PubMedGoogle Scholar
• 22 Asherson R A, Pierangeli S S, Cervera R. Is there a microangiopathic antiphospholipid syndrome?.  Ann Rheum Dis. 2007;  66 429-432
  PubMedGoogle Scholar
• 23 Ter Borg E J, Van Der Meer J, De Wolf J TM et al.. Arterial thrombotic manifestations in young women associated with the lupus antocoagulant.  Clin Rheumatol. 1988;  7 74-79
  CrossrefPubMedGoogle Scholar
• 24 Asherson R A, Cervera R. Sneddon's and the “primary” antiphospholipid syndrome: confusion clarified.  J Stroke Cerebrovasc Dis. 1993;  3 121-122
  PubMedGoogle Scholar
• 25 Gómez-Puerta J A, Cervera R, Calvo L M et al.. Dementia associated with the antiphospholipid syndrome: clinical and radiological characteristics of 30 patients.  Rheumatology. 2005;  44 95-99
  CrossrefPubMedGoogle Scholar
• 26 Asherson R A, Cervera R. Antiphospholipid antibodies and the heart: lessons and pitfalls of the cardiologist.  Circulation. 1991;  84 920-923
  PubMedGoogle Scholar
• 27 Morton K E, Gavaghan T P, Krilis S A et al.. Coronary artery bypass graft failure: an autoimmune phenomenon?.  Lancet. 1986;  ii 1353-1356
  CrossrefPubMedGoogle Scholar
• 28 Sandoval J, Amigo M-C, Barragan R et al.. Primary antiphospholipid syndrome presenting as chronic thromboembolic pulmonary hypertension. Treatment with thromboendarterectomy.  J Rheumatol. 1996;  23 772-775
  PubMedGoogle Scholar
• 29 Rich S, Kieras K, Hart K, Groves B M, Stobo J D, Brundage B H. Primary pulmonary hypertension.  J Am Coll Cardiol. 1986;  8 1307-1311
  CrossrefPubMedGoogle Scholar
• 30 Asherson R A, Cervera R. Pulmonary hypertension, antiphospholipid antibodies and syndromes.  Clin Rev Allergy Immunol. 2007;  32 153-158
  PubMedGoogle Scholar
• 31 Asherson R A, Cervera R, Pierangeli S S. Microangiopathic antiphospholipid-associated syndromes revisited; new concepts relating to antiphospholipid antibodies and syndromes.  J Rheumatol . 2007;  34 1793-1795
  PubMedGoogle Scholar
• 32 Hughson M D, Madasdy T, McCarty G A, Stoler C, Min K-W, Silva T. Renal thrombotic microangiopathy in patients with systemic lupus erythematosus and the antiphospholipid syndrome.  Am J Kidney Dis. 1992;  20 150-158
  PubMedGoogle Scholar
• 33 Radhakrishnan J, Williams G S, Appel G B, Cohen D J. Renal transplantation in anticardiolipin antibody-positive lupus erythematosus patients.  Am J Kidney Dir. 1994;  23 286-289
  PubMedGoogle Scholar
• 34 Espinosa G, Santos E, Cervera R et al.. Adrenal involvement in the antiphospholipid syndrome: clinical and immunologic characteristics of 86 patients.  Medicine (Baltimore). 2003;  82 106-118
  CrossrefPubMedGoogle Scholar
• 35 Cervera R, Espinosa G, Cordero A for the Catastrophic Antiphospholipid Syndrome (CAPS) Registry Project Group et al.. Intestinal involvement secondary to the antiphospholipid syndrome (APS): clinical and immunologic characteristics of 97 patients: comparison of classic and catastrophic APS.  Semin Arthritis Rheum. 2007;  36 287-296
  CrossrefPubMedGoogle Scholar
• 36 Espinosa G, Font J, García-Pagan J C et al.. Budd-Chiari syndrome secondary to antiphospholipid syndrome: clinical and immunologic characteristics of 43 patients.  Medicine (Baltimore). 2001;  80 345-354
  CrossrefPubMedGoogle Scholar
• 37 Triplett D A. Antiphospholipid antibodies and recurrent pregnancy loss.  Am J Reprod Immunol. 1989;  20 52-67
  PubMedGoogle Scholar
• 38 Cervera R, Piette J C, Font J et al.. on behalf of the “Euro-Phospholipid Project Group.” Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients.  Arthritis Rheum. 2002;  46 1019-1027
  CrossrefPubMedGoogle Scholar
• 39 Erkan D, Cervera R, Asherson R A. Catastrophic antiphospholipid syndrome: where do we stand?.  Arthritis Rheum. 2003;  48 3320-3327
  CrossrefPubMedGoogle Scholar
• 40 Bucciarelli S, Espinoza G, Cervera R et al.. Mortality in the antiphospholipid syndrome; causes of death and prognostic factors in 250 patients.  Arthritis Rheum. 2006;  54 2568-2576
  CrossrefPubMedGoogle Scholar
• 41 Erdozain J G, Ruiz-Irastorza G, Egurbide M V et al.. Sustained response to rituximab of autoimmune hemolytic anemia associated with antiphospholipid syndrome [abstract].  Haematologica. 2004;  89 ECR34
  PubMedGoogle Scholar
• 42 Rubenstein E, Arkfeld D G, Metyas S, Shinada S, Ehresmann S, Liebman H A. Rituximab treatment for resistant antiphospholipid syndrome.  J Rheumatol. 2006;  33 355-357
  PubMedGoogle Scholar
• 43 Yamazaki M, Kawashima Y, Asakura H, Nakao S. Rituximab decreases antiphospholipid antibody titers and improves hypercoagulable state without recurrent thrombosis: 2-year follow-up [abstract].  Thromb Res. 2004;  114 610
  PubMedGoogle Scholar
• 44 Crowther M A, Ginsberg J S, Julian J et al.. Comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome.  N Engl J Med. 2003;  349 1133-1138
  CrossrefPubMedGoogle Scholar
• 45 Finazzi G, Marchioli R, Brancaccio V et al.. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS).  J Thromb Haemost. 2005;  3 848-853
  CrossrefPubMedGoogle Scholar
• 46 Kearon C. Long-term management of patients after venous thromboembolism.  Circulation. 2004;  110(Suppl 1) 110-118
  PubMedGoogle Scholar
• 47 Erkan D, Harrison M J, Levy R et al.. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals.  Arthritis Rheum. 2007;  56 2382-2391
  CrossrefPubMedGoogle Scholar
• 48 Goldstein L B, Adams R, Alberts M J et al.. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council.  Circulation. 2006;  113 e873-e923
  CrossrefPubMedGoogle Scholar
• 49 Erkan D, Leibowitz E, Berman J et al.. Perioperative medical management of antiphospholipid syndrome: hospital for special surgery experience, review of literature, and recommendations.  J Rheumatol. 2002;  29 843-849
  PubMedGoogle Scholar
• 50 Erkan D. The relation between antiphospholipid syndrome-related pregnancy morbidity and non-gravid vascular thrombosis: Review of the literature and management strategies.  Curr Rheumatol Rep. 2002;  4 379-386
  CrossrefPubMedGoogle Scholar
• 51 Derksen R H, Khamashta M A, Branch D W. Management of the obstetric antiphospholipid syndrome.  Arthritis Rheum. 2004;  50 1028-1039
  CrossrefPubMedGoogle Scholar
• 52 Erkan D, Lockshin M D. New treatments for antiphospholipid syndrome.  Rheum Dis Clin North Am. 2006;  32 129-148
  CrossrefPubMedGoogle Scholar

5 deceased

Ricard CerveraM.D. 

Servei de Malalties Autoimmunes, Hospital Clinic

Villarroel 170, 08036 Barcelona, Catalonia, Spain

Email: rcervera@clinic.ub.es